Outcomes in GLP-1 receptor agonists
Glucagon-like peptide-1 receptor agonists may increase the risk of adverse gastrointestinal outcomes.
In an umbrella review published in JAMA Network Open, investigators used the PubMed, Web of Science, Embase, Scopus and Cochrane Database of Systematic Reviews to identify 60 meta-analyses involving more than 1,700 randomized clinical trials and over 3.5 million participants. They sought to assess GLP-1 receptor agonist outcomes beyond their previously recognized cardiometabolic effects. These included gastrointestinal, respiratory, neurologic, psychiatric, hepatic, endocrine, cancer and fracture outcomes.
The investigators found that participants who received GLP-1 receptor agonists experienced a greater risk of adverse gastrointestinal events, including nausea, vomiting and diarrhea. However, they identified protective effects of the drugs on respiratory and severe infection outcomes.
Because the results of the study were based on low-certainty evidence, the investigators emphasized that clinicians should employ individualized treatment approaches when considering GLP-1 receptor agonists and that further studies are needed to validate the association between the drugs and noncardiometabolic outcomes.
Read more: JAMA Network Open
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.